Tags: Drug.
Solanezumab (proposed INN) is a monoclonal antibody being investigated by Eli Lilly as a neuroprotector for patients with Alzheimer’s disease.It binds to the amyloid-β peptides that make up the protein plaques seen in the brains of people with the disease.2012 results of the EXPEDITION 1 & 2 phase 3 clinical trials were only mildly encouraging. but were said to be the first evidence that targeting the amyloid cascade can slow the progression of disease.”